Navigation Links
Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript
Date:5/16/2008

CEDAR KNOLLS, N.J., May 16 /PRNewswire-FirstCall/ -- Highlighting the company's expectations for the future as well as its current product pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies, Inc. (Nasdaq: EMIS), was featured in an extensive interview published recently in The Wall Street Transcript (TWST). Established more than 40 years ago, TWST interviews the leaders of financial markets, including CEOs, analysts and money managers, and publishes their viewpoints, opinions and recommendations.

In his interview, Mr. Novinski discussed the two most important objectives for the company moving forward: "We want to bring our technology to the commercial level as soon as possible," he said, "and build our early and mid-stage pipeline with additional partnerships, expecting to add three new partnerships during 2008."

Mr. Novinski also explained Emisphere's proprietary eligen(R) technology and its applications for drug delivery to address a number of medical conditions. He said that the technology needs to come from the clinical experimental stage to the commercial level. "At that point we will be able to demonstrate that, in fact, our technology can provide benefits to the population at large, for whatever treatment it is we are talking about," Mr. Novinski explained.

One of those treatments is for Vitamin B12 deficiency. Emisphere has completed two successful animal studies using its eligen(R) technology for an oral formulation of Vitamin B12, and expects to be conducting studies in humans by mid-year, Mr. Novinski told TWST. "We believe there should be an opportunity to commercialize our technology [with our oral Vitamin B12 formulation] as early as next year."

Mr. Novinski also discussed the company's current partnerships, highlighted by "two very exciting products with Novartis that are already well into Phase III [development]." Through this program, "by the middle of this year, more than 5,000 patients will be taking Emisphere's eligen(R) technology with Salmon Calcitonin for the treatment of osteoarthritis and osteoporosis," explained Mr. Novinski. "That's very exciting."

The entire Wall Street Transcript interview can be viewed at Emisphere's Website, http://www.emisphere.com.

ABOUT EMISPHERE TECHNOLOGIES, INC.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology; convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. In those cases, use of Emisphere's technology can improve the therapeutic effectiveness of the compounds. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding potential third party collaborations, future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that one or more potential third party collaborations may not be consummated, that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed on May 7, 2008.


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
5. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016 - I dati ... durante il 52 ° Congresso ... - Le conclusioni dello studio indicano un ... trattati, di cui il 90% presenta una d urata ... più. Il settantadue per cento dei pazienti ha riscontrato un ...
(Date:5/18/2016)... The Biotech industry continues to face a wave ... no opportunities ahead. Today, ActiveWallSt.com has on its list these ... Seattle Genetics Inc. (NASDAQ: SGEN ), Chiasma Inc. ... OPHT ). Sign up now to receive our free ... Threshold Pharmaceuticals Inc.,s shares gained 0.68%, closing Tuesday,s ...
(Date:5/18/2016)... IN (PRWEB) , ... May 18, 2016 , ... The ... and is now celebrating its dream of reaching a total of $1 million in ... scholarships awarded to 10 high school graduates from across the nation has helped bring ...
(Date:5/17/2016)... ... May 17, 2016 , ... ... animal waste reduction applications, announced today it will be showcasing ManureMagicâ„¢ at booth ... ManureMagicâ„¢ was featured in the Wall Street Journal last year and more recently ...
Breaking Biology Technology:
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... and DE SOTO, Kansas ... U.S.-based Stroke Detection Plus® to offer Oncimmune,s Early ... assessment and early detection of lung cancer ... employers, unions and individuals. --> Early CDT®-Lung ... and individuals. --> Oncimmune, a leader in ...
Breaking Biology News(10 mins):